KURA

Kura Oncology, Inc.

20.38 USD
+0.13 (+0.64%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kura Oncology, Inc. stock is up 13.35% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Jan 16:38 19 Apr, 2024 25.00 CALL 851 25
30 Jan 20:50 16 Feb, 2024 20.00 PUT 715 1530
31 Jan 14:35 16 Feb, 2024 20.00 CALL 200 2207
02 Feb 17:10 19 Apr, 2024 25.00 CALL 370 6233
02 Feb 18:29 16 Feb, 2024 17.50 CALL 100 1184
02 Feb 19:39 19 Jul, 2024 30.00 CALL 309 82
02 Feb 20:00 19 Apr, 2024 22.50 CALL 284 64
07 Feb 18:35 19 Jul, 2024 22.50 CALL 98 105
08 Feb 16:29 19 Jul, 2024 22.50 PUT 118 64
09 Feb 17:50 15 Mar, 2024 22.50 CALL 500 5555

About Kura Oncology, Inc.

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.